Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kala

Lucid Group bolsters its senior client services team with two magical new hires

Lucid Group boosts its senior client services team with the arrival of David Pearce and Sandra Burke, both as client operational directors.With 15 years of Med Comms experience, David has...

Lucid Group Communications Limited

- PMLiVE

NHS leaders warn of no-deal Brexit flu vaccine delays

Follows prior delay in production of the vaccine

- PMLiVE

Sanofi patent case win holds off generic rivals for key cancer drug

Boosts hope of increasing future sales

Lucid Group supercharges its client services team with four spellbinding new hires

Lucid Group makes four magical additions to its client services team!Annabel Lloyd joins Vivid as an account director. With experience in a variety of therapy areas from immunology, oncology, CVD...

Lucid Group Communications Limited

- PMLiVE

The fight for affordable insulin

Activists are organised, and demanding action on US insulin prices - and pointing the finger at pharma

- PMLiVE

Dupixent drives Sanofi again, but other new drugs are lagging

Reported loss due to restructuring

Bluedog is bursting with new creative and digital talent

Bluedog, a Lucid Group company, welcomes four spellbinding new additions to its team.With a strong background in animation, Rachel Sparks joins Bluedog as a motion designer. Having previously worked in...

Lucid Group Communications Limited

- PMLiVE

FDA verdict on Sanofi’s Darzalex rival is due in April 2020

One of several anti-CD38 antibodies in pipeline

- PMLiVE

M&F Health, 90TEN and Sanofi among big winners at Communiqué Awards

Full results from health comms awards

- PMLiVE

NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

Acknowledges unmet need

- PMLiVE

Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

Licensed to treat one of the most commonly diagnosed skin cancers

- PMLiVE

FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

Could add $1bn to revenues, say analysts

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links